13 results about "INSULIN HUMAN" patented technology

The present invention relates to a test kit for performing an assay to detect and measure at least one autoantibody molecule in a subject developing type 1 diabetes (T1D). The invention more specifically relates to a recombinant antigen molecule fused to a bioluminescent reporter protein to detect an autoantibody molecule against a self-antigen. Said self-antigen is preferably expressed by pancreatic islet beta cells and include insulin, proinsulin, Glutamate decarboxylase 65, islet antigen 2, and Zinc transporter 8. More specifically, the present invention relates to an assay comprising a set of at least three recombinant antigen molecules in a single composition, the antigen molecules being selected from the list comprising recombinant human Glutamate decarboxylase 65, recombinant human islet antigen 2, recombinant human Zinc transporter 8, recombinant human insulin, and recombinant human proinsulin. The invention further relates to methods for determining the presence and / or level of at least one autoantibody molecule in a sample from a human subject developing T1D using said recombinant antigen molecules. According to the invention, the presence, absence, or amount of one or more autoantibody molecules against said self-antigens is determined with a luciferase immune precipitation system (LIPS) assay or a modified version of a LIPS assay, i.e., a solid phase capture LIPS (scLIPS) assay.

This invention belongs to the field of immune cell culture technology, specifically relating to an in vitro expansion culture medium for NK cells and its culture method. It consists of a basal culture medium and auxiliary additives. The basal culture medium is X-VIVO 15 medium; the auxiliary additives include the following components: human serum albumin (HSA), IL-12, IL-18, IL-15, rapamycin, nicotinamide, gelatin-IL-15 microspheres, alginate-IL-21 microspheres, recombinant human insulin, transferrin, glutamine, β-mercaptoethanol, a mixture of non-essential amino acids and lipids. This invention achieves time-dependent synergistic IL-15 sustained-release / IL-21 pulsed release and metabolic synergistic NAD+ release. + Mitochondrial / lipid membrane homeostasis enables efficient amplification and long-lasting cytotoxicity.

The application discloses a kind of active human insulin solution standard substance with interchangeability and its preparation method and application, belong to chemical metrology analytical detection technical field.The preparation method provided in the application includes the purification of human insulin, self-assembly of human insulin, confirmation of insulin self-assembly complex structure, the purification of active human insulin, determination of immunological affinity active concentration and specific activity, preparation of active human insulin solution standard substance with interchangeability.The above preparation method provided in the application can be used for the calibration of human insulin routine in vitro diagnostic system, the development of in vitro diagnostic detection reagent and method performance verification, and for the value traceability of human insulin detection result in serum, ensure the accuracy and comparability of clinical detection result, protect public health and life safety.

The application relates to the technical field of stem cells, in particular to a mesenchymal stem cell culture system without heterogeneity and application thereof. The mesenchymal stem cell culture system without heterogeneity comprises a basic culture medium and an additive component, wherein the basic culture medium is DMEM / F12, and the additive component comprises: recombinant human transferrin, recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin, recombinant human interferon gamma, hydrocortisone, vitamin A, vitamin D2, vitamin B, human blood albumin, CTS KnockOut SR XenoFree, glutamine and dextran. The mesenchymal stem cell culture system without heterogeneity provided by the application improves the proliferation efficiency of primary culture and in-vitro expansion culture of mesenchymal stem cells, is high in safety, good in stability and suitable for large-scale popularization and application.

This invention relates to a kit and method for detecting anti-human insulin-like growth factor binding protein 7 (IGFBP-7) using a double-antibody sandwich principle combined with a nucleic acid probe self-assembly signal amplification method. The kit comprises three parts: 1) a capture domain formed by IGFBP-7 antibody 1 coated on the surface of an ELISA plate; 2) a tandem functional domain composed of biotin-labeled IGFBP-7 antibody 2, streptavidin, and biotin-labeled DNA primers; and 3) a fluorescence signal functional domain composed of two DNA hairpin probes. Compared with traditional ELISA methods, the method of this invention significantly improves detection sensitivity and features high specificity, high sensitivity, good stability, and strong versatility, as well as good clinical application value.

The invention provides a product for treating type 2 diabetes mellitus based on a stem cell insulin gene vector. The product consists of mesenchymal stem cells modified by genetic engineering and a cell preservation solution, the genetic engineering modified mesenchymal stem cells are obtained by transducing human mesenchymal stem cells by using a recombinant lentiviral vector, and the recombinant lentiviral vector can express a fusion protein composed of three parts of human proinsulin, a linker peptide and a GLP-1 receptor agonist. According to the application, human proinsulin and a GLP-1 receptor agonist are constructed into a single fusion protein, human mesenchymal stem cells are transduced by utilizing a lentiviral vector, and then a standardized three-stage induced differentiation process is carried out, so that a cell therapy product which can intelligently respond to blood glucose changes for a long time and has stable functions is finally obtained. The defects of transient treatment effect, single secretion function and large cell product batch-to-batch difference in the prior art are fundamentally overcome.

The invention relates to a pharmaceutical composition containing human insulin analogue fusion protein and application thereof. The pharmaceutical composition has good biological activity and stability.

The present invention relates to a nucleic acid molecule comprising a nucleotide sequence encoding a metabolic protein or a portion thereof, or a sequence having at least 90% sequence identity to said metabolic protein or a portion thereof, a human insulin-like growth factor II (IGFII) gene sequence, and a nucleotide sequence encoding at least one peptide that promotes cellular uptake or transcytosis inserted into said IGFII gene sequence between the nucleotides encoding amino acids 28 and 42 of mature IGFII. The invention further relates to related viral particles, fusion proteins, and uses thereof.

The invention relates to nucleic acid molecules comprising a nucleotide sequence encoding a metabolic protein or a part thereof or a sequence having at least 90% sequence identity to said metabolic protein or part thereof, a human insulin-like growth factor II (IGFII) gene sequence, and a nucleotide sequence encoding at least one peptide that facilitates cellular uptake or transcytosis which is inserted at a location between the nucleotides encoding amino acids 28 and 42 of mature IGFII of said IGFII gene sequence. The invention further relates to related viral particles, fusion proteins and uses thereof.

The invention discloses an induction method of dopaminergic neural stem cells, and relates to the technical field of cell culture and neurobiology, and the induction method comprises the following steps: inoculating neural stem cells into an induction culture medium, culturing under the conditions of 37 DEG C and 5% CO2, and carrying out induced differentiation for 6-14 days to obtain dopaminergic neurons; the induction culture medium takes DMEM / F12 as a basic culture medium, and contains an effective amount of the following components: human insulin, progesterone, hydrocortisone, dexamethasone, estradiol, transferrin, an epidermal growth factor (EGF) and a fibroblast growth factor (FGF). The induction culture medium and the method have the advantages that the survival of neural stem cells can be effectively supported; and the gene is guided to directionally differentiate towards the dopaminergic neuron lineage. The method is clear in operation flow and stable in differentiation process, the expression of the characteristic marker of the dopaminergic neuron can be detected in the obtained cell population, and a stable and reliable cell source is provided for related scientific research.

This invention relates to the field of NK cell culture medium technology, and discloses an NK cell culture medium, its preparation method, and its applications, including: an activation phase culture medium, an expansion phase culture medium, and a maturation phase culture medium; wherein the three culture media include a common combination of recombinant human transferrin, recombinant human insulin, polyvinyl alcohol, ethanolamine, ascorbate-2-phosphate, α-thioglycerol, sodium selenite, ferric citrate monohydrate, and nicotinamide, as well as different combinations of cytokines. This invention uses polyvinyl alcohol instead of recombinant human serum albumin. Polyvinyl alcohol can form a physical protective layer to stabilize the cell membrane and act as a surfactant to disperse hydrophobic nutrients, thereby more efficiently and stably supporting cell survival and proliferation. The culture medium of this invention, combined with the three-stage culture method of this invention, can effectively maintain high cytotoxicity of cells and significantly reduce the expression of functional exhaustion-related molecules while obtaining high-purity NK cell expansion.

The invention discloses a culture medium for promoting separation of Wharton's jelly mesenchymal stem cells, application and a method, and belongs to the technical field of mesenchymal stem cell culture. The culture medium comprises a basic culture medium, a recombinant human basic fibroblast growth factor, a recombinant human hepatocyte growth factor, recombinant human insulin, recombinant human transferrin, a recombinant human stromal cell-derived factor (SDF-1alpha), lycopene and a ginseng extract. The culture medium provided by the invention is free of serum and heterologous components, the climbing-out speed and number of Wharton's jelly mesenchymal stem cells can be remarkably increased, and the dryness of the mesenchymal stem cells can be well maintained.